chronic myelomonocytic leukaemia (CMML) | Page 7 | Aplastic Anemia & MDS International Foundation Return to top.

chronic myelomonocytic leukaemia (CMML)

Clinical Trials and Children

Until recently, children were rarely included in studies of medical treatments. As a result, much is still unknown about how children respond to drugs, some biologics (such as gene therapy) and medical devices. According to the U.S. Food and Drug Administration (FDA), only 20-30% of approved drugs have actually been labeled for use in children.

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer
For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines in patients with solid cancers, such as lung, breast, or prostate cancer.
November 2021 – Lung Cancer
Laura Morgan

ASTEX PHARMACEUTICALS PRESENTS OVERALL SURVIVAL DATA FROM ASCERTAIN PHASE 3 STUDY OF ORAL HYPOMETHYLATING AGENT INQOVI® (DECITABINE AND CEDAZURIDINE) IN MDS AND CMML AT INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES

Study achieved median overall survival of 31.7 months
Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response

Dr. Jason Mendler

Mendler, Jason
Assistant Professor of Oncology
Wilmot Cancer Center

Jason Harold Mendler, MD, PhD, Assistant Professor of Oncology, received his bachelor's degree, Summa Cum Laude, from Washington University in St. Louis, Missouri. He then went on to earn his PhD in Genetics and his medical degree at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Prior to joining Wilmot Cancer Center, Dr. Mendler completed his residency at and served as chief resident of the University of Rochester Medical Center, Department of Medicine.

Share with addtoany.com.